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Secondary visual loss occurs in millions of patients due to a wound-healing response, known as 
posterior capsule opacification (PCO), following cataract surgery. An intraocular lens (IOL) is implanted 
into residual lens tissue, known as the capsular bag, following cataract removal. Standard IOLs allow 
the anterior and posterior capsules to become physically connected. This places pressure on the IOL 
and improves contact with the underlying posterior capsule. New open bag IOL designs separate 
the anterior capsule and posterior capsules and further reduce PCO incidence. It is hypothesised 
that this results from reduced cytokine availability due to greater irrigation of the bag. We therefore 
explored the role of growth factor restriction on PCO using human lens cell and tissue culture models. 
We demonstrate that cytokine dilution, by increasing medium volume, significantly reduced cell 
coverage in both closed and open capsular bag models. This coincided with reduced cell density 
and myofibroblast formation. A screen of 27 cytokines identified nine candidates whose expression 
profile correlated with growth. In particular, VEGF was found to regulate cell survival, growth and 
myofibroblast formation. VEGF provides a therapeutic target to further manage PCO development and 
will yield best results when used in conjunction with open bag IOL designs.
Cataract is the leading cause of blindness worldwide1. It is estimated that by the year 2020 that 32 million peo-
ple will require cataract removal surgery2. While cataract surgery initially yields a good restoration of vision, 
secondary visual loss results following a wound-healing response within the remaining lens tissue; this leads to 
cells encroaching within the visual axis, deforming the underlying collagenous posterior capsule and depositing 
additional matrix components. These changes cause light scatter and consequently visual deterioration, which 
is known as posterior capsule opacification (PCO), “after-cataract” or “secondary cataract”. PCO is treated by 
ablation of light-scattering material from within the visual axis using laser surgery. With an ever-increasing life 
expectancy, cataract and PCO will become an even greater problem, both in terms of patient well-being3 and eco-
nomic burden4. Therefore, further advances in our understanding of this condition is essential to develop better 
management in the future.
An important part of most cataract surgeries is to implant an artificial intraocular lens (IOL), which sits within 
the remaining lens capsules, which are commonly referred to as the capsular bag. The capsular bag hosts the IOL 
to maintain stability and position, which allows best restoration of visual quality. Design and material modi-
fications to IOLs in the past 20 years have significantly improved and reduced the time to PCO presentation5. 
However, the increase in cataract surgeries and our increasing aging population is now countering this reduction. 
1.82 million cataract operations are performed in the USA annually, costing Medicare $3.4 billion each year4, and 
making cataract surgery the most common surgical procedure performed by healthcare providers. Furthermore, 
recent studies are demonstrating that the rates of clinically relevant PCO development at 10 years post cataract 
surgery are rising6. Although cataract is regarded as an aging disorder, the age of cataract removal is decreasing, 
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perhaps as a consequence of populations working further into old age and therefore a greater necessity for good 
vision. Certainly in many countries the age at which cataract surgery is undertaken has decreased6. PCO therefore 
continues to be a considerable problem associated with cataract patient care.
IOL designs currently incorporate a square-edge motif on the posterior side of the IOL optic and rely on a 
closed capsular bag IOL arrangement. As the capsular bag “shrink wraps” the IOL subsequent to implantation 
the square-edge works as a physical barrier pressing into the posterior capsule preventing invading lens epithe-
lial cells progressing on to the posterior capsule7. This effectively delays the time for PCO to present. However, 
eventually this physical barrier is breached and the lens epithelial cells rapidly proceed onto the posterior capsule. 
More recent studies on innovative IOL devices are demonstrating a way to further impact on posterior cell cover 
compared with classical closed capsular bag IOL systems. These open capsular bag designs keep the posterior and 
anterior capsules separated following IOL implantation8–10. This allows aqueous humour into the capsular bag 
space and this flow of aqueous humour is thought to help wash-out and reduce growth factor levels contained 
within the capsular bag that are upregulated as a response to cataract surgery.
Gaining a greater understanding of the processes that govern PCO progression and the benefits of IOL design 
are essential if we are to produce effective, sustainable and affordable therapies for eliminating PCO. The purpose 
of this study was to use human cell and tissue models to test the hypothesis that growth factor dilution (predicted 
with open bag IOLs) could reduce PCO and to better understand which growth factors and cytokines play key 
roles in PCO related events. Our study found that a general reduction in growth factor availability significantly 
impeded cell invasion on the posterior capsule and myofibroblast expression. These findings support the idea of 
open bag IOLs for use in cataract surgery. Moreover, we determined that a number of cytokines could influence 
growth characteristics of human lens cells and in particular it was found that VEGF plays a key role in growth and 
transdifferentiation. Consequently, inhibition of VEGF/VEGFR signalling is a logical target for future strategies 
to prevent PCO development in addition to improved IOL design.
Results
Increasing the volume of bathing media results in a decrease in cell cover on the posterior cap-
sule of human capsular bags. The coverage of cells on the anterior capsule following surgery was observed 
and found to vary between donors, but was similar with respect to capsular bags from the same donor. With 
culture, there was no discernible difference in the point in time at which cells passed the rhexis edge on to the 
previously cell-free central posterior capsule in capsular bags cultured in 1.5 ml or 6 ml SF (serum-free) EMEM 
(4.2 ± 0.9 and 3.9 ± 1.1 days respectively). A notable difference in cell cover was observed at day 8 between the 
1.5 ml and 6 ml cultures. 7 out of 10 capsular bag pairs had greater cover on the posterior capsule within the rhexis 
region at this time point in the 1.5 ml compared to the 6 ml cultures, and 2 out of the 10 capsular bag pairs had no 
cell cover in the rhexis region in either the 1.5 ml or the 6 ml cultures. However, overall no significant difference 
was observed (Fig. 1). By culture day 13 the difference in cell cover between the match-pairs was significant, such 
that there was 60.5 ± 10.8% cover in the 1.5 mls and a 35.1 ± 7.9% cover in the 6 ml capsular bag cultures (Fig. 1). 
At day 28 (end-point) the 1.5 ml capsular bags still had significantly greater cell cover on the central posterior 
capsule region compared to 6 ml counterparts, such that coverage was 71.8 ± 10.6% and 39.1 ± 10.1% respectively 
(Fig. 1).
Cell density is decreased with increasing media volume in human capsular bags. The cell density 
on the posterior capsule region of closed capsular bag cultures at end-point (day 28) was found to be significantly 
less in 6 ml SF EMEM cultures compared to 1.5 ml cultures (66.6 ± 22.9 and 154.3 ± 26.2 respectively, Fig. 2). 
Additionally, the number of cells in the anterior capsule region was markedly reduced in the 6 ml cultures com-
pared to the 1.5 ml but this difference was not significant (Fig. 2).
Epithelial Mesenchymal Transition (EMT) is decreased in cells on the posterior capsule with 
increased medium volume in human capsular bag cultures. In order to evaluate EMT on the capsu-
lar bag, the well-established myofibroblast marker α SMA was determined11. At end-point (day 28) a significant 
reduction in α SMA expression was observed in cells growing on the posterior capsule within the capsulorhexis 
region of capsular bags cultured in 6 ml SF EMEM compared with levels observed in counterparts maintained in 
1.5 ml SF EMEM, such that levels of 37.2% ± 10.0% and 100.0% ± 0.0% respectively were determined, (Fig. 3).
Separating the anterior and posterior capsules to create open capsular bag cultures retards 
cell cover on the posterior capsule of human capsular bags. Match-paired open capsular bags main-
tained in 1.5 ml SF EMEM had very little cell coverage of the central posterior capsule region at endpoint (Day 28; 
Fig. 4). In fact cell cover was only observed in one (of three) open capsular bag maintained in 1.5 ml SF EMEM 
(Fig. 4). No cell coverage was observed in the central posterior capsule region in open capsular bags maintained 
in 6 mls SF EMEM (Fig. 4).
Open match-paired capsular bags were also maintained in 1.5 ml and 6 ml 5%FCS supplemented EMEM. 
Complete coverage of the central posterior capsule region was obtained by day 12 of culture in both 1.5 ml 
and 6 ml counter parts (data not shown). This suggests that the reduction in cell cover observed in SF EMEM 
open-bag cultures can be negated by the addition of exogenous cytokines/growth factors (within serum).
Cytokine analysis by 27-plex Bioplex identifies cytokines/growth factors that are significantly 
reduced in the bathing media of 6 ml capsular bag cultures compared to 1.5 ml. Analysis of 
media collected from closed capsular bag preparations at culture day 2 demonstrated that 24 cytokines were 
detectable in bathing media from both 1.5 ml and 6 ml cultures (Fig. 5). While one would predict that all cytokines 
would be diluted four fold with increasing culture medium volume it is important to note that this is a biologi-
cal system that is capable of reacting to its changing environment. Consequently only 9 cytokines (IL-8, IL-15, 
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IL-12(p70), MCP-1, MIP-1β , IL-1ra, IL-10, IP-10 and VEGF) were found to have significantly reduced levels in 
the media of capsular bags maintained in 6 mls SF compared to 1.5 ml (Fig. 5). This pattern correlates with growth 
across the capsular bag and as a result these 9 candidates were studied further to assess their ability to stimulate 
survival and growth.
Figure 1. Posterior capsule cell cover: (a,b) Comparison of 1.5 ml and 6 ml SF EMEM treated match-paired 
capsular bags cultured over a 28-day period. (a) Phase micrographs at day 0 showing no cell cover on the central 
posterior capsule viewed via the anterior capsule rhexis. (a,b) Cell progression has advanced onto the central 
posterior capsule region at day 8 of culture in both 1.5 ml and 6 ml cultures, this cell cover is not significantly 
different. (a,b) At Day 13 significantly greater cell cover is observed on the central posterior capsule in 1.5 ml 
cultures compared to 6 ml counter. (a,b) Day 28 (end-point) of culture almost complete cell cover of the central 
posterior capsule observed in 1.5 ml capsular bags compared with a significant reduction in cell cover in 6 ml 
counterparts. The data are expressed as Mean ± SEM (n = 10). *Indicates significant difference between the 
1.5 ml and 6 ml groups (P ≤ 0.05, Students t test). Average age of donor was 72.8 ± 2.7 years.
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Stimulation of FHL 124 cell growth by cytokine candidates. The addition of IL-10, IL-12, IL-15, 
IL-1ra, IP-10, MCP-1 or MIP1β to the human lens cell line FHL 124 cultured in SF EMEM resulted in signifi-
cant cell population increases after 48 hours relative to non-stimulated controls (Fig. 6). Generally, this response 
occurred in a dose-dependent manner. However, the addition of IL-8 and VEGF did not result in a change in the 
cell population. This outcome is particularly interesting in relation to VEGF because it is highly expressed in the 
bathing media of 1.5 ml capsular bag cultures (Fig. 5) and raises the possibility that endogenous VEGF could be 
a key survival/growth factor.
VEGF receptor expression in human lens cells. The expression of VEGFR1 and VEGFR2, also known as 
flt1 and KDR respectively, were determine in FHL 124 cells using real-time PCR. Both receptors were detectable, but 
the signal for VEGFR2 was consistently greater (Fig. 7). These data demonstrating the presence of VEGF receptors 
allied to detection of VEGF in the culture medium indicates that VEGF/VEGFR autocrine signalling can take place.
Inhibition of VEGF receptors reduces cell viability, growth and transdifferentiation of FHL 
124 cells. Treatment with the pan-specific VEGF receptor inhibitor Axitinib at 10 μM lead to a significant 
reduction in cell population following a 72 hour culture period (Fig. 8a). No significant changes were observed 
with lower concentrations (0.1 and 1 μM). To see if the reduction in cell population associated with 10 μM 
treatment corresponded with increase cell death the LDH assay was employed. This analysis demonstrated no 
greater loss in LDH with 0.1 or 1 μM Axitinib relative to control, but a significant increase was observed with 
10 μM (Fig. 8b). To better observe the changes taking place within the 72 hour culture period and further assess 
Figure 2. Cell density decreases with media dilution: (a,b) Comparison of cell population numbers in 1.5 ml 
and 6 ml SF EMEM treated match-paired capsular bags cultured for 28-days. (a) Epifluorescence micrographs 
at day28 showing a marked decrease in cell numbers on the anterior capsule in 6 ml culture compared to 1.5 ml 
counter-parts. Cell population numbers were determined by chromatin staining with DAPI (4′ ,6-diamidino-2-
phenylindole). This decrease in cell number was not significantly different. (a,b) Epifluorescence micrographs 
at day 28 showing a significant decrease in cell numbers on the posterior capsule in 6 ml culture compared to 
1.5 ml counter-parts. The data are expressed as Mean ± SEM (n = 8). *Indicates significant difference between 
the 1.5 ml and 6 ml groups (P ≤ 0.05, Students t test).
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Figure 3. EMT decreases with media dilution: (a,b) Comparison of the expression of myofibroblastic cell 
marker α SMA in 1.5 ml and 6 ml SF EMEM treated match-paired capsular bags cultured for 28-days. (a,b) 
Epifluorescence micrographs at day 28 show a significant decrease in α SMA expression in cells on the central 
posterior capsule in 6 ml cultures compared to 1.5 ml counter-parts. The data are expressed as Mean ± SEM 
(n = 8). *Indicates significant difference between the 1.5 ml and 6 ml groups (P ≤ 0.05, Students t test). α SMA 
expression shown in green.
Figure 4. Capsule separation decreases cell growth: Comparison of 1.5 ml and 6 ml SF EMEM treated 
match-paired open capsular bags cultured for 28 days. Phase micrographs at end-point (day 28) showing 
limited cell cover on the central posterior capsule (as marked by yellow line) in 1.5 ml open bag cultures and no 
cell cover in 6 ml counterparts. The location of the anterior rhexis was super-imposed. Cell cover past the super-
imposed anterior rhexis edge indicates there was no significant difference in cell cover between the 1.5 ml and 
6 ml open capsular bags groups. Replicate match-paired experiments n = 3. Average age of donor was 71.0 ± 3.1 
years.
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Figure 5. Comparison of growth factor/cytokine levels in 1.5 ml and 6 ml SF EMEM treated match-paired 
capsular bags at day 2 of culture. (a) Shows cytokines that increased in concentration in response to medium 
dilution and (b) shows those that were lower in 6 ml cultures relative to 1.5 ml counterparts. Cytokine levels 
in media of closed match-paired capsular bag cultures maintained in SF EMEM was analysed by a suspended 
bead array multiplex cytokine panel. Data expressed as Mean ± SEM (n = 10). *Indicates significant difference 
between the 1.5 ml and 6 ml groups (P ≤ 0.05, Students t test). Average age of donor was 72.8 ± 2.7 years.
www.nature.com/scientificreports/
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the impact of VEGFR inhibition a scratch wound-healing assay was used. Employing this method demon-
strated that after 24 hours of culture, a significant decrease in cell migration was detected when comparing 
Axitinib (10 μM) treated cells to SF controls (Fig. 9). At this stage the cells look generally healthy, but as the 
period of culture extended to 48 hours some evidence of cell death was apparent in the treated group whereas 
migration progressed in the control cells. This pattern continued to end-point (72 hours) when notable distress 
to cells with Axitinib treatment had occurred (Fig. 9). The effect of VEGFR inhibition on transdifferentiation 
was also assessed using the myofibroblast cell marker, α SMA as a measure. Addition of Axitinib (10 μM) 
to FHL 124 cells for 48 hrs significantly decreased the protein levels of α SMA to 56.4 ± 11.5% (Fig. 10) of 
non- treated control cells. This EMT response was also examined at the message level using real-time PCR. 
Using this method it was found that ACTA2, the gene encoding α SMA was significantly reduced with Axitinib 
treatment. In addition, EMT/fibrosis associated genes, FN1 and MMP2 gene expression was also significantly 
Figure 6. Cytokine addition increases cell proliferation: Specific cytokine addition to human lens cell line 
FHL 124 cells over a 48 hr period increases cell proliferation. No increase in cell proliferation was observed 
with concentrations of IL-8 and VEGF. Cell proliferation detected by alcohol extraction of Coomassie blue 
protein dye. The data are expressed as mean ± SEM (n = > 4). *Indicates significant difference to control  
(P ≤ 0.05, Students t test).
Figure 7. Quantitative comparison of VEGFR1/Flt-1 and VEGFR2/KDR gene expression in FHL 124 cells. 
The y-axis represents the gene of interest/18S expression calculated as mean ± SEM (n = 4).
www.nature.com/scientificreports/
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suppressed with VEGFR inhibition (Fig. 11). This collection of data support the notion that VEGF is important 
for cell survival, growth and transdifferentiation of human lens cells.
VEGFR inhibition reduces PCO related events in a human in vitro capsular bag culture sys-
tem. There was no significant difference in the point at which cells passed the rhexis edge on to the central 
posterior capsule in capsular bags cultured in Axitinib (10 μM) 1.8 ± 0.2 days compared to control counterparts 
1.6 ± 0.2 days. However, a significant difference could be observed by day 8 in cell cover of the central posterior 
capsule region with Axitinib (10 μM) treatment compared to controls, such that coverage in these two groups 
was 27.9 ± 6.1% and 86.4 ± 8.1% respectively (Fig. 12). This difference in cell cover was retained throughout 
the culture period with a significant difference still observed at day 13 of culture, with 95.1 ± 4.6% cover seen 
in control bags and 39.3 ± 7.8% for Axitinib (10 μM) treated counterparts (Fig. 12). At endpoint (Day 28) the 
control capsular bags had almost complete cell coverage of the central posterior capsule region with an average of 
96.5 ± 3.5%, whilst the Axitinib (10 μM) treated counterparts had a significantly reduced cell cover of 48.5 ± 8.0% 
(Fig. 12). Further evaluation at end-point to assess levels of α SMA in cells growing on the central posterior cap-
sule, demonstrated a significant reduction in transdifferentiation with VEGFR inhibition relative to non-treated 
controls, such that levels of 53.2% ± 11.4% and 100.0% ± 0.0% respectively were determined, (Fig. 13).
Discussion
The development of open bag IOL devices has opened up a new avenue in the management of PCO following 
cataract surgery. The separation of the anterior and posterior lens capsules is believed to allow greater irrigation 
of the capsular bag, which in turn hypothetically reduces cytokine/growth factor enrichment to remaining lens 
cells. This reduced supply of stimuli is predicted to limit the rate of PCO progression. In the current study we 
demonstrate that dilution of cytokines/growth factors by increased culture medium volume, to mimick greater 
irrigation, significantly retards growth across the previously cell free posterior capsule and leads to reduced 
myofibroblast formation. Attenuation of these events support the notion that open bag IOLs can provide benefit 
to cataract patients through restriction of PCO. In addition, we identified that expression of several cytokines/
growth factors correlated with cell growth following simulated cataract surgery on donor eyes. Of these we deter-
mined that endogenous VEGF in particular played an important role in lens cell survival, growth and transdif-
ferentiation and thus provides a therapeutic target to further manage PCO development in conjunction with 
improved IOL designs.
Figure 8. VEGF receptor inhibition modulates cell population and toxicity: (a) Addition of Axitinib (10 μm) to 
FHL 124 cells cultured in SF EMEM over a 72 hr period caused a significant decrease in cell population.  
(a) No significant changes in cell populations were found with exposure to 0.1 and 1 μM Axitinib compared to 
control. (b) A significant increase in cell toxicity was observed with the addition of 10 μM Axitinib but not with 
exposure to 0.1 and 1 μM Axitinib. Cell population detected by alcohol extraction of Coomassie blue protein 
dye. Cell toxicity assessed by total LDH using commercially available kit (Promega). The data are expressed as 
mean ± SEM (n = 3). *Indicates significant difference to control (P ≤ 0.05, Students t test).
www.nature.com/scientificreports/
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The IOL is an important component in the management of PCO following cataract surgery. At present a square 
edge acrylic IOL with a 360 degree contact of the anterior capsulorhexis on the optic body is regarded as best prac-
tice12,13. This strategy allows the anterior and posterior capsules to come in contact and through a cell mediated pro-
cess these surfaces are fused, which in turn ‘shrink wraps’ the IOL within the capsular bag. The forces exerted through 
this process increase tension of the capsule against the square edge of the optic and this forms a physical barrier that 
impedes the progression of cells across the visual axis14. Adoption of the square-edge IOL implant has reduced PCO, 
but in time this barrier is overcome and cells progress onto the posterior capsule leading to a reduction in visual 
quality. Square edge IOLs afford some benefit to patients, but there is still considerable scope to develop IOLs that 
better contain PCO. Open bag designs are beginning to emerge15,8 and early reports both in pre-clinical and clinical 
scenarios suggest that this approach is effective16,17. It is hypothesised that greater irrigation of the capsular bag will 
limit cytokines/growth factor availability to lens cells, which in turn will limit PCO progression. Previously, we have 
shown that an open bag IOL is more effective at reducing cell progression on to the posterior capsule in comparison 
to a leading square-edge closed bag IOL9. Our findings support this idea. In our study, to mimick greater dilution of 
growth factors that is predicted with open bag IOLs, we simply cultured cells in different culture medium volumes. 
These were closed bags without an IOL implanted and interesting results were obtained. First of all the time at which 
cells appeared on the central posterior capsule, beyond the capsulorhexis margin of match-paired cultures did not 
differ, suggesting that a lack of irrigation in the closed compartment rendered growth in these closed environments 
independent of total culture volume. Once cells reached the exposed central posterior capsule the greater culture 
volume took effect and growth was restricted and interestingly at end-point, transdifferentiation was also reduced. 
These findings suggest that the proximity of the anterior and posterior capsules is important for cell progression. It is 
likely that the cells present in this region provide adequate enrichment of growth factors to neighbouring cells and it 
is also likely that adsorption of growth factors to matrix components within the lens capsule will accrue and provide 
an available resource. Interestingly when the capsular bag was fully opened, such that all internal surfaces were laid 
flat and directly exposed to culture medium, cell growth onto the posterior capsule was significantly restricted. This 
Figure 9. VEGF receptor inhibition affects cell migration: (a) Addition of Axitinib (10 μM) to FHL 124 cells 
cultured in SF EMEM over a 3 day period caused a significant decrease in cell migration compared to SF 
Controls. (a) This decrease was less than control conditions indicating that Axitinib (10 μM) was additionally 
affecting cell survival. (b) Cell migration was determined using a scratch-wound healing assay and measuring 
cell movement from the leading edge with Image J analysis software. The data are expressed as mean ± SEM 
(n = 3). *Indicates significant difference to SF Control (P ≤ 0.05, Students t test).
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finding ties in with the idea that within a closed system cytokine/growth factor production is better able to support 
the cell populations. In the fully open system lower concentrations are likely to result and potentially, matrix bound 
growth factors will be less. Exposure of multiple cytokines/growth factors by serum addition promoted growth 
across the posterior capsule, which again supports the idea that a shortfall in stimuli is a rate limiting factor. Having 
demonstrated the restriction of growth and transdifferentiation through irrigation and separation of the lens cap-
sules it is important to consider, which cytokines/growth factors are regulating events following surgery? In order to 
assess multiple cytokines/growth factors we employed a suspended bead cytokine array analysis of medium samples. 
The capsular bag system is dynamic and responsive to its environment. It was, therefore, uncertain whether culture 
in a four-fold greater medium volume would result in a quarter of the level of growth factors. Consequently, we 
needed to identify which cytokines/growth factors were present and how they were modified by a change in culture 
medium volume. In some cases, levels actually went up with greater culture volume suggesting a cellular response 
to the situation. However, we were particularly interested in the factors that showed a significant decrease in levels 
with greater culture volume, which would correlate with PCO related events. We found nine candidates using this 
screen. These were IL-1ra, IL-8, IL-10, IL-12(p70), IL-15, IP-10, MCP-1, MIP-1β and VEGF. A number of these 
cytokines have been linked to cell growth and other fibrotic conditions18,19. IL-10, while not directly linked to prolif-
eration does demonstrate a correlation in expression with VEGF levels and it is proposed that IL-10 mediates VEGF 
expression20. Similarly, MCP-1 is also reported to regulate proliferation through endogenous VEGF21. This could be 
through increased synthesis or greater liberation of VEGF from matrix associated stores. VEGF is known to bind to 
heparan sulphate proteoglycans (HSPGs)22, which are abundant on the lens capsule23,24. Therefore, increased levels 
of VEGF as a consequence of cataract surgery could bind to the capsule and provide a sustained supply of VEGF that 
can mediate long-term changes. VEGF can be released from extracellular matrix by plasmin cleavage25 or MMPs26. 
Our previous studies have demonstrated that MMPs increase in culture media following cataract removal surgery27,28 
and thus could perform this function. In the lens capsular bag model, levels of MMPs are known to rise and thus it 
is feasible that this could be linked to specific cytokines. Using cell culture systems we demonstrated that exogenous 
application of all, but IL-8 and VEGF were capable of promoting further lens epithelial cell growth. With respect to 
IL-8 and VEGF, it should be noted that both of these candidates were expressed at relatively high levels in 1.5 ml cul-
tures and thus it is possible that they contribute greatly to endogenous maintenance of lens epithelial cells. As a con-
sequence we decided to adopt an inhibition strategy and elected to concentrate our efforts on VEGF because there 
are established inhibitors29–31 and a range of therapeutic agents commonly used in the clinic to treat the wet form of 
Figure 10. Alpha smooth muscle actin expression: (a,b) Axitinib (10 μM) decreased protein levels of the 
myofibroblastic marker α SMA in FHL 124 cells. FHL 124 cells were treated with either Axitinib (10 μM) or 
SF EMEM for 48 hrs following which protein was extracted. (a,b) Western blot analysis shows a significant 
decrease in α SMA in FHL 124 cells exposed to Axitinib (10 μM) for 48 hrs compared to SF EMEM treated 
controls. (a,b) Data were normalised to β -Actin control. Data are expressed as Mean ± SEM (n = 3). *Indicates 
significant difference between the Control and Axitinib (10 μM) groups (P ≤ 0.05, Students t test). Samples 
for each experiment were run on the same gel and processed in parallel. All gels were run under the same 
experimental conditions. The representative western blots are cropped images and full-length blots are 
presented in Supplementary Figure 1.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:24453 | DOI: 10.1038/srep24453
age-related macular degeneration (AMD)32. Using this approach we found that VEGFR inhibition could significantly 
retard growth and restrict myofibroblast formation.
We hypothesised that endogenous VEGF was a survival/growth factor for human lens epithelial cells.
This theory was supported by the inhibition study data as cell growth was suppressed in both cell line and 
capsular bag experiments. It was also apparent that cell death was observed over time, which was more apparent 
in the cell line than capsular bags, which could suggest that differences in matrix composition or cell density 
could be important factors. As PCO is a fibrotic condition, the effects of VEGF inhibition on myofibroblast for-
mation is of interest. Our findings demonstrated that VEGFR inhibition could significantly decrease α SMA, a 
myofibroblast marker, in both the cell line and in capsular bags. This pattern of response also compares to the 
results obtained for capsular bags cultured in greater media volume. These studies were performed to investigate 
Figure 11. The influence of VEGF receptor inhibition using Axitinib (10 μM) on EMT/fibrotic marker genes 
(a) ACTA2 (b) FN1 and (c) MMP2 in FHL 124 cells. Cells were maintained in experimental conditions for 
24 hours and gene expression was detected using TaqMan real-time PCR. Expression of the gene of interest 
was normalised to 18S expression. The data represent Mean ± SEM (n = 3). *indicates a significant difference 
between treatment and control group ((P ≤ 0.05, Students t test).
www.nature.com/scientificreports/
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Figure 12. Posterior capsule cell cover: (a,b) Comparison of SF EMEM Control Vs Axitinib (10 μM) treated 
match-paired capsular bags cultured over a 28 day period. (a) Phase micrographs at day 0 showing no cell cover 
on the central posterior capsule viewed via the anterior capsule rhexis. (a) Cell progression has advanced onto 
the central posterior capsule region at day 8 of culture in both Control and Axitinib (10 μM) treated cultures.  
(b) This cell cover is significantly different between the match-paired counterparts. (a,b) Indicating a 
significantly greater cell cover on the central posterior capsule in Control cultures compared to Axitinib (10 μM) 
treated counter-parts at day 13 of culture. (a,b) Day 28 (end-point) of culture indicating almost complete 
cell cover of the central posterior capsule in Control capsular bags compared with a significant reduction in 
cell cover in Axitinib (10 μM) treated counterparts. Data are expressed as Mean ± SEM (n = 5). *Indicates 
significant difference between the Control and Axitinib (10 μM) groups (P ≤ 0.05, Students t test). Average age 
of donor was 63.0 ± 5.0 years.
www.nature.com/scientificreports/
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modification of baseline levels of α SMA in response to surgical injury. It is likely that TGFβ levels will rise in the 
eye33 and that exposure of lens cells to this stimulus will increase myofibroblast numbers34–36. It will therefore be 
of great interest in the future to test the effects of VEGF inhibition on TGFβ -induced myofibroblast formation.
It should be noted that the current study employed pan-specific VEGFR inhibitor (Axitinib). While this 
served as an excellent tool to identify the key roles of VEGF in PCO related events it does not allow analysis 
of the relative contributions of VEGFR sub-types. Future studies could utilise more selective inhibitors against 
individual VEGFRs or if required siRNA knockdown. One possibility is to apply the inhibitor to the aqueous or 
vitreous humour at the time of surgery. This approach, however, is dependent on adverse effects on non-lenticular 
tissue. An alternative strategies is to deliver the drug to lens cells through localised drug delivery36–39. This can be 
achieved by modification of the intraocular lens surface36,40–42, however, important consideration is required to 
reduce the effect of abrasion of the surface when implanted through a narrow injection device. These lenses are 
folded prior to implantation and coating an inner surface could be preferable. While this principle applies to any 
IOL based on our findings it would be most effect if an open bag IOL is used. Another method that provides local 
delivery to lens cells is the perfect capsule system37,39,43. This clinical tool provides a seal over the capsulorhexis. 
Through an irrigation port a drug can be introduced for a designated period of time and removed through an 
aspiration port. This approach allows controlled delivery and can be used in any cataract surgery independent 
of which IOL is implanted. While VEGFR inhibitors provide a therapeutic option it should be noted that several 
therapies for wet AMD target VEGF with the majority being antibody based43. Again similar modes of delivery, 
as described for the inhibitors could be used. These therapeutic agents have the benefit of being FDA approved for 
use in the eye and thus could be adopted for use in cataract patients without major delay.
Conclusions
The data elucidated from this project adds to the body of data revealing that changes in IOL design to an “open 
bag” device could substantially reduce the rate of PCO development. Here open capsular bag in vitro cultures 
showed a significant decrease in cell cover of the posterior capsule compared to closed capsular bag prepara-
tions. This supports the idea that improved irrigation using open bag IOLs limits growth factor availability and 
suppresses PCO like events, such as cell growth and myofibroblast expression. Further adaptation to open bag 
designs by modification of open bag IOL devices with inhibitors to VEGF could further enhance the inhibi-
tory effect on cell progression to the posterior capsule following cataract removal. Prevention of PCO using this 
method will maintain a greater level of visual quality, reduce the need for secondary surgery and potential provide 
a marked financial benefit to healthcare providers.
Figure 13. EMT decreases with VEGFR inhibition: (a,b) Comparison of the expression of myofibroblastic 
cell marker α SMA in Control and Axitinib (10 μM) SF EMEM treated match-paired capsular bags cultured for 
28-days. (a,b) Epifluorescence micrographs at day 28 show a significant decrease in α SMA expression in cells 
on the central posterior capsule in Axitinib treated cultures compared to Control counter-parts. The data are 
expressed as Mean ± SEM (n = 5). *Indicates significant difference between the Control and Axitinib groups  
(P ≤ 0.05, Students t test). α SMA expression shown in green.
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Materials and Methods
All reagents were from Sigma-Aldrich (Poole, Dorset, UK) unless otherwise stated.
Capsular bag preparations. Cataract operations were performed on human donor lenses to create capsular 
bags from that were obtained with informed consent and used in accordance with the tenets of the Declaration of 
Helsinki. Approval for the study and experimental protocols (04/Q0102/57) was granted by a national research 
ethics committee under the Health Research Authority (UK). Relevant information relating to the donors is pro-
vided in the Supplementary data section (Table 1). A small capsulorhexis was made in the centre of the anterior 
lens capsule through which the fibre-cell mass of the lens was removed by hydro-expression. This created the 
capsular bag consisting of the entire “cell-free” posterior capsule and a ring of anterior capsule with its associated 
anterior lens epithelial cells. The capsular bag was then dissected from the globe by cutting through the zonules 
of Zinn. The capsular bag was then pinned onto 35 mm petri dishes (Corning Incorporated Life Sciences, New 
York, USA) using entomological pins (Anglia Lepidopterist supplies, Hindolveston, Norfolk, UK). This resulted 
in a closed capsular bag preparation (Fig. 14). All capsular bags contained similar starting populations of anterior 
lens epithelial cells.
Capsular bags were subsequently maintained in either non-supplemented SF EMEM (Eagles, minimum essen-
tial medium) containing Gentamicin antibiotic (50 μg/mL) at a volume of 1.5 ml or 6 mls or SF EMEM containing 
Gentamicin antibiotic (50 μg/mL) ± Axitinib (10 μM) (Selleckchem (Stratech Scientific Ltd), Newmarket, Suffolk, 
UK)). Capsular bag preparations were maintained for 28 days in a 35 °C, 5% CO2 incubator and experimen-
tal conditions replenished every 2–3 days. Ongoing observations were performed using a Nikon Eclipse TE200 
phase-contrast microscope and phase contrast images taken. End point analysis of cell coverage on the previously 
cell-free posterior capsule was assessed with Image J analysis software (http://rsb.info.nih.gov/ij/), using the area 
of the anterior capsulorhexis formed during the cataract operation as a control. Complete cell coverage of the pos-
terior capsule as observed thorough the created anterior capsulorhexis was scored as 100% cell coverage, the effect 
of experimental conditions on the progression of lens epithelial cells onto the posterior capsule was evaluated.
Open bag preparations were created as above but following creation of the anterior capsulorhexis radial inci-
sions were made in the anterior capsule and the resultant anterior capsule “wings” pinned open (Fig. 15). The 
fibre-cell mass of the lens was removed and the preparations cultured in either 1.5 ml or 6 ml SF EMEM contain-
ing Gentamicin antibiotic (50 μg/mL) for 28 days. Ongoing observations were performed using a Nikon Eclipse 
TE200 phase-contrast microscope and phase contrast images taken. End-point analysis of cell coverage on the 
previously cell-free posterior capsule was assessed with Image J analysis software (http://rsb.info.nih.gov/ij/), the 
area of the anterior capsulorhexis was super-imposed on the posterior capsule image and cell coverage of the pos-
terior capsule measured within the super-imposed rhexis region. Complete cell coverage of this area was scored 
as 100% cell coverage, the effect of media volume increase on the progression of anterior lens epithelial cells onto 
the posterior capsule was evaluated.
FHL 124 cells. The foetal human lens epithelial cell-line FHL 124 used in this study has previously been 
shown to have 99.5% homology with native human lens epithelium44,45. FHL 124 cells were kindly provided by 
Prof. J. R. Reddan (Oakland University, Rochester, MI).
Cell proliferation. FHL 124 cells were seeded onto 96 well mictotitre plates (Thermoscientific, Cramlington, 
Northumberland, UK) at a density of 2500 cells per well and maintained for 3 days in 5% FCS EMEM supple-
mented with Gentamicin antibiotic (50 μg/mL) in a 35 °C 5% CO2 incubator before 24 hr serum starvation. Media 
was then aspirated and replaced with increasing dose response of the following cytokines IL-8, IL-15, IL-12(p70), 
Figure 14. Diagram of closed capsular bag preparation from a human donor lens. 
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MCP-1, MIP-1β , IL-1ra, IL-10, IP-10 and VEGF for 48 hrs. At experimental end points media was aspirated and 
cells fixed with 4% formaldehyde in PBS (Oxoid Ltd, Basingstoke, Hampshire, UK) for 30 minutes, formaldehyde 
was subsequently removed and cells washed with PBS 3 times for 5 minutes. To each well 200 μl of Coomassie 
blue protein stain (1 g Coomassie brilliant blue G (Merck, Darmstadt, Germany), 200 ml methanol, 40 ml glacial 
acetic acid (Fisher, Scientific UK Ltd, Loughborough, UK), 100 ml dH2O) was added for 30 minutes and the 
plate placed on a microtitre plate shaker (Heidolph instruments, Schwabach, Germany). Coomassie blue stain 
non-specifically binds proteins and can therefore be used to determine cell population numbers. After 30 minutes, 
the Coomassie blue stain was removed by several washes in PBS. To each well 200 μl of 70% ethanol was added 
and the plate placed on a microtitre plate shaker (Heidolph instruments, Schwabach, Germany) for 30 minutes to 
elute the bound dye. The plate was then read at 550 nm absorbance on a BMG Fluostar spectrophotometer plate 
reader (BMG Labtech, Aylesbury UK). Data was analysed as a percentage change in absorbance at 550 nm from 
untreated samples.
Cell toxicity. FHL 124 cells were seeded onto 96 well mictotitre plates (Thermoscientific, Cramlington, 
Northumberland, UK) at a density of 2500 cells per well. At experimental end-points media was collected 
and 100 μl of each sample added to a well on a new 96 well mictotitre plates (Thermoscientific, Cramlington, 
Northumberland, UK). To determine LDH content in the cells 100 μl of 2% Triton X-100 in PBS was added to 
each well to lyse the cells and the plate placed on a microtire plate shaker (Heidolph instruments, Schwabach, 
Germany) for 30 minutes. Following this time 10 μl of the lysate was transferred to wells on a separate microtitre 
plate and 90 μl of SF EMEM added. A non-radioactive cytotoxicity assay (Roche, Germany) was used to measure 
the amount of lactate dehydrogenase (LDH) in both the sampled media and the lysate. The procedure was in 
accordance with the manufacturer’s protocol. The absorbance of all samples was recorded at 490 nm using a BMG 
Fluostar spectrophotometer plate reader (BMG Labtech, Aylesbury UK). The percentage of total LDH released 
into the culture medium was calculated using the following formula media/(media + lysateX10)*100.
Scratch wound-healing assay. FHL 124 cells were seeded on to 35 mm tissue culture dishes (Corning 
Incorporated Life Sciences, New York, USA) at a density of 50000 cells/dish and maintained in SF EMEM supple-
mented with 5% FCS and Gentamicin antibiotic (50 μg/mL) until a confluent region spanning approximately 1 cm 
developed. Media was then aspirated and replaced with non-supplemented SF EMEM with Gentamicin antibiotic 
(50 μg/mL) and cultured for a further 24 hrs. Subsequently, a scratch was made through the centre of the confluent 
sheet using a plastic pipette tip and the cells removed from one half of the dish using a cell scraper. Orientation 
marks were made near the wound edge to create a reference point. Ongoing observations were performed using 
a Nikon Eclipse TE200 phase-contrast microscope and phase contrast images taken. The change in area covered 
over time in each experimental condition was calculated from the phase contrast images using Fiji (Fiji Is Just 
Image J) Image J analysis software (http://fiji.sc/Fiji).
Western blotting. Following culture of FHL 124 cells in SF EMEM or Axitinib (10 μM, Selleckchem (Stratech 
Scientific Ltd), Newmarket, Suffolk, UK)) for 48 hrs cells were immediately quickly washed with ice-cold 
PBS (phosphate buffered saline). Ice-cold PBS was aspirated and replaced with 350 μl of MPER lysis buffer 
(Thermoscientific, Cramlington, Northumberland, UK) containing 5 mM EDTA and 10 μl/mL of both protease 
and phosphotase inhibitor cocktails (Thermoscientific, Cramlington, Northumberland, UK). Following a 5 min-
ute incubation on ice, cells were detached from dishes using a cell-scraper and the resultant lysates carefully 
collected and transferred to 1.5 ml Eppendorf tubes and centrifuged for 10 minutes at 1300λ PM. Soluble frac-
tions were transferred to fresh 0.5 ml Eppendorfs tubes and stored at −20 °C, whilst the insoluble fractions were 
discarded.
To ensure an equal quantity of protein for each sample was loaded on to SDS-PAGE gels a BCA (Bicinchronic) 
protein assay was performed. A protein standard series ranging from 0–1000 μg/ml was generated from a 2 mg/
ml BSA in lysis buffer stock solution. Ten micro-litres of each standard and unknown sample were pipetted 
into individual wells of a transparent 96-well microtitre plate (Thermoscientific, Cramlington, Northumberland, 
UK), along with 40 μl of double distilled water. Protein standards were tested in triplicate, whilst all unknown 
samples were tested in duplicate. Working reagent (BCA™ protein assay kit, Thermoscientific, Cramlington, 
Northumberland, UK) at a volume of 200 μl was added to each well (concentration 1:50) and the plate was gently 
shaken on a microtitre plate shaker for 1 minute prior to a 1 hr incubation at 35 °C. Subsequently the plate was left 
Figure 15. Diagram of open capsular bag preparation from a human donor lens. 
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at room temperature to cool for 5 minutes and then analyzed in a BMG Fluostar spectrophotometer plate reader 
(BMG Labtech, Aylesbury UK) at a setting at 565 nm. The protein concentration of each unknown sample could 
then be calculated from the standard dilution series. Equal amounts of protein from each sample were loaded onto 
10% SDS-PAGE gels for electrophoresis, and then transferred onto PVDF membrane (NEN Life Science Products, 
Boston, MA, USA) using a Trans-Blot semi-dry Transfer Cell (Bio-Rad, Hemel Hempstead, Hertfordshire, UK). 
Subsequently the membrane was blocked with a PBS solution containing Tween (1:2000, Fisher Scientific UK 
Ltd, Loughborough, UK) and milk protein (0.5%) to block non-specific sites for 1 hour. Specific proteins were 
probed using Anti-α SMA (1:1000) and Anti-β -Actin (1:1000) Cell Signalling Technology, Hitchin, Hertfordshire, 
UK) overnight at 4 °C. Following the incubation period the membranes were washed a further 6 times for 5 min-
utes per wash and then incubated for a further hour in secondary HRP antibody (1:2000 GE Healthcare, Little 
Chalfont, Buckinghamshire, UK). After secondary antibody incubation the membranes were washed a further 
5 times in PBS solution containing Tween (1:2000, Fisher Scientific UK Ltd, Loughborough, UK) and milk pro-
tein (0.5%) before a final wash in PBS containing tween (1:1000, Fisher Scientific UK Ltd, Loughborough, UK) 
without milk protein. The chemoluminescent ECL Prime was then added to the membrane (GE Healthcare, 
Little Chalfont, Buckinghamshire, UK) for 5 minutes in the dark, before the membrane was exposed to Hyperfilm 
ECL photographic paper (GE Healthcare, Little Chalfont, Buckinghamshire, UK) in a dark room. The photo-
graphic paper was developed using developing solution, and the developer halted with stop solution (Photosol, 
inc Hallandale, FL, USA), before the photographic paper was made transluscent with Fixer solution (ILFORD 
PHOTO, Knutsford, Cheshire, UK). The resultant protein bands on the photographic film were scanned on a 
flatbed scanner and measured using image J analysis software (http://rsb.info.nih.gov/ij/).
Total RNA extraction and cDNA generation. Total RNA was extracted from FHL 124 cells (seeded at 
density of 50,000 cells in 5% FCS + EMEM) that were then replaced with SF-EMEM one day prior to treatment. 
Experimental conditions were then applied and the cells harvested for RNA following a 24 hour period, accord-
ing to the manufacturers instructions for the RNeasy micro kits (Qiagen, West Sussex, UK). In the initial step, 
RLT buffer (containing β -mercaptoethanol) was added to Eppendorf tubes containing cell lysates. The samples 
were then homogenized through a 20 gauge needle (0.9 mm) and syringe. The remainder of the protocol was as 
described by the manufacturer and included a DNase step. RNA was quantified using a NanoDrop ND-1000 
spectrophotometer (NanoDrop, Wilmington, DE). For each round of RNA extracted, the ratio of absorptions 
at 260/280 nm ranged from 1.8 to 2.2 (mean = 2.0). Where possible, total RNA was immediately used for cDNA 
generation or briefly stored for up to a week at −80 °C. Generation of cDNA was performed with Superscript II 
reverse transcriptase (Invitrogen, Paisley, UK) according to the reverse transcription (RT) protocols of the man-
ufacturer using random primers (Promega, Southampton, UK).
Quantitative Real time Polymerase Chain Reaction (QRT-PCR). Real time PCR was used to quan-
titate target gene expression in FHL 124 cells relative to an endogenous control gene (18S). Oligonucleotide 
primers and fluorescence-labeled probes for fibrotic markers (ACTA2, FN-1 and MMP2) and VEGFR genes 
were ordered from Life Technologies (Supplementary Table 2). Assuming 100% efficiency in the RT reactions, 
either 1 or 5 ng cDNA was used in real-time PCR reactions performed using a real-time PCR machine (ABI7700; 
Applied Biosystems). Reagent-based assays (TaqMan Universal PCR Master Mix, No AmpErase® UNG; Applied 
Biosystems) containing all PCR reagents were employed according to the manufacturer’s instructions. Conditions 
for the PCR reaction were; 2 min at 50 °C, 10 min at 95 °C and then 40 cycles, each consisting of 15s at 95 °C and 
1 min at 60 °C. The cycle number at which amplification entered the exponential phase (raw data cycle threshold 
[CT]) was determined and this number was used as an indicator for the amount of target RNA in each sam-
ple. In raw data analyses the CT value was used to classify gene expression as either very high (CT ≤ 22), high 
(CT = 23–25), moderate (CT = 26–28), low (CT = 29–34), or negligible to undetected (CT = 35–40). To deter-
mine the relative RNA levels in the samples, standard curves for each primer/probe set were prepared by using 
cDNA from one sample and making twofold serial dilutions covering the range equivalent to 20–0.625 ng RNA 
(for 18S analysis the range was from 1 to 0.03125 ng). Differences in the total amount of RNA present in each 
sample were normalized to endogenous 18S rRNA gene expression.
Immunocytochemistry. Capsular bags were cultured in SF EMEM containing Gentamicin antibiotic 
(50 μg/mL) at a volume of 1.5 ml or 6 mls or SF EMEM containing Gentamicin antibiotic (50 μg/mL) ± (10 μM) 
Axitinib (Selleckchem (Stratech Scientific Ltd), Newmarket, Suffolk, UK)) maintained for 28 days. At end-point 
culture medium was aspirated from capsular bag culture dishes and the tissue washed 3 times in quick succession 
with PBS. Subsequently capsular bags were fixed in 1.5 ml of 4% formaldehyde in PBS solution for 30 minutes. 
The capsular bags were then bisected and each section transferred to a new 35 mm petri dish and washed for a 
further 3 times with a solution of PBS containing 0.02% Bovine Serum Albumen (BSA) and 0.05% Igepal. The 
cell membranes were permeabilised in PBS containing 0.5% Triton-X100 for 30 minutes. A further 3 washes 
in PBS containing 0.02% BSA and 0.05% Igepal were completed for a time period of 15 minutes per wash on a 
plate shaker. Non-specific cellular sites were blocked with Normal Goat Serum (1:50) in 1% BSA in PBS, and 
incubated for 1 hr at 37 °C. Following the blocking procedure 75μl of primary antibody for α SMA (1:100) was 
added to the tissue and capsular bags incubated for a further hour at 37 °C. Capsular bags were then washed 
for 15 minutes with shaking in PBS containing 0.02% BSA and 0.05% Igepal and this was repeated twice more. 
Secondary antibody (mouse anti-goat 488, Thermoscientific, Cramlington, Northumberland, UK) at a volume 
of 75 μl (1:200) was added to tissue and incubated for another hour at 37 °C in the dark. The Actin filament 
stain Texas Red X-Phalloidin (Thermoscientific, Cramlington, Northumberland, UK) 1:100 in PBS containing 
1% BSA along with the chromatin stain DAPI (1:100) were added to preparations for ten minutes in the dark at 
room temperature. The capsular bags were washed a further three times in PBS containing 0.02% BSA and 0.05% 
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Igepal with shaking in the dark for 10 minute durations. Capsular bags sections were mounted on microscope 
slides (Thermoscientific, Cramlington, Northumberland, UK) using Hydromount (National Diagnostics, Atlanta, 
Georgia, USA) mounting solution and left to dry for 30 minutes at room temperature in the dark and were sub-
sequently viewed under a Zeiss CCD Upright epifluorescent microscope and analyzed using Axiovision 4.9.1 
imaging software. Cell populations were quantified using Image J analysis (http://rsb.info.nih.gov/ij/) and α SMA 
expression levels with Image Pro Analysis software.
Suspended Bead Array Analysis. Culture media was sampled on day 2 from capsular bag preparations 
maintained in either 1.5 ml or 6 ml SF EMEM. Media was analysed for cytokines IL-1β , IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, IL-1ra, VEGF, G-CSF, FGF (Basic), MIP-1α , MCP-1(MCAF), 
IP-10, RANTES, GM-CSF, IFNγ , TNFα , MIP-1β , Eotaxin and PDGF-BB using a commercially available 27-Plex 
panel (Bio-Plex Suspended Multiplex Bead Array Assay kit; Bio-Rad, Hemel Hempstead, UK) in accordance with 
manufacturer’s instructions. Data from the reactions were acquired with a flow cytometry system (X Map-100; 
Luminex, Austin, Texas, USA) and accompanying software (Bio-Plex Manager software; Bio-Rad). The median 
fluorescence intensity was used as a measure of detected protein.
Statistical analysis. Statistical differences between groups were established using Student’s t-test with a 
p-value of ≤ 0.05 considered significant (Microsoft Excel).
References
1. Resnikoff, S. et al. Global data on visual impairment in the year 2002. B World Health Organ 82, 844–851, doi: /S0042-
96862004001100009 (2004).
2. Thylefors, B. A global initiative for the elimination of avoidable blindness. Indian J Ophthalmology 46, 129–130 (1998).
3. Wormstone, I. M., Wang, L. X. & Liu, C. S. C. Posterior capsule opacification. Exp Eye Res 88, 257–269, doi: 10.1016/j.exer.2008. 
10.016 (2009).
4. Brown, G. C. et al. Cataract surgery cost utility revisited in 2012: a new economic paradigm. Ophthalmology 120, 2367–2376, doi: 
10.1016/j.ophtha.2013.04.030 (2013).
5. Spalton, D. Posterior capsule opacification: have we made a difference? Brit J Ophthalmol 97, 1–2, doi: 10.1136/bjophthalmol- 
2012-302570 (2013).
6. Lundqvist, B. & Monestam, E. Ten-year longitudinal visual function and Nd: YAG laser capsulotomy rates in patients less than 65 
years at cataract surgery. Am J Ophthalmol 149, 238-244 e231, doi: 10.1016/j.ajo.2009.08.029 (2010).
7. Nishi, O. & Nishi, K. Preventing posterior capsule opacification by creating a discontinuous sharp bend in the capsule. J Cataract 
Refract Surg. 25, 521–526 (1999).
8. Alon, R., Assia, E. I. & Kleinmann, G. Prevention of posterior capsule opacification by an intracapsular open capsule device. Invest 
Ophth Vis Sci. 55, 4005–4013, doi: 10.1167/iovs.14-14364 (2014).
9. Eldred, J. A., Spalton, D. J. & Wormstone, I. M. An in vitro evaluation of the Anew Zephyr open-bag IOL in the prevention of 
posterior capsule opacification using a human capsular bag model. Invest Ophth Vis Sci 55, 7057–7064, doi: 10.1167/iovs.14-15302 
(2014).
10. Hara, T., Hara, T., Sakanishi, K. & Yamada, Y. Efficacy of equator rings in an experimental rabbit study. Arch Ophthalmol 113, 1060– 
1065 (1995).
11. Hinz, B. Myofibroblasts. Exp Eye Res 142, 56–70, doi: 10.1016/j.exer.2015.07.009 (2016).
12. Hayashi, K. & Hayashi, H. Posterior capsule opacification in the presence of an intraocular lens with a sharp versus rounded optic 
edge. Ophthalmology 112, 1550–1556, doi: 10.1016/j.ophtha.2005.03.024 (2005).
13. Nanavaty, M. A., Spalton, D. J., Boyce, J., Brain, A. & Marshall, J. Edge profile of commercially available square-edged intraocular 
lenses. J Cataract Refract Surg 34, 677–686, doi: 10.1016/j.jcrs.2007.12.024 (2008).
14. Boyce, J. F., Bhermi, G. S., Spalton, D. J. & El-Osta, A. R. Mathematical modeling of the forces between an intraocular lens and the 
capsule. J Cataract Refract Surg 28, 1853–1859 (2002).
15. Kavoussi, S. C. et al. Prevention of capsular bag opacification with a new hydrophilic acrylic disk-shaped intraocular lens. J Cataract 
Refract Surg 37, 2194–2200, doi: 10.1016/j.jcrs.2011.05.049 (2011).
16. Leishman, L. et al. Prevention of capsular bag opacification with a modified hydrophilic acrylic disk-shaped intraocular lens. J 
Cataract Refract Surg 38, 1664–1670, doi: 10.1016/j.jcrs.2012.04.040 (2012).
17. Hara, T. et al. Long-term study of posterior capsular opacification prevention with endocapsular equator rings in humans. Arch 
Ophthalmol 129, 855–863, doi: 10.1001/archophthalmol.2011.38 (2011).
18. Chaudhary, N. I. et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29, 976–985, doi: 
10.1183/09031936.00152106 (2007).
19. Sime, P. J. & O’Reilly, K. M. A. Fibrosis of the lung and other tissues: New concepts in pathogenesis and treatment. Cl Immunol 99, 
308–319 (2001).
20. Nagata, J. et al. Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer. 
Int J Mol Med 10, 169–172 (2002).
21. Parenti, A., Bellik, L., Brogelli, L., Filippi, S. & Ledda, F. Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on 
vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 286, H1978–1984, doi: 10.1152/ajpheart.00414.2003 (2004).
22. Xu, D., Fuster, M. M., Lawrence, R. & Esko, J. D. Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability. 
J Biol Chem 286, 737–745, doi: 10.1074/jbc.M110.177006 (2011).
23. Wu, W. et al. A gradient of matrix-bound FGF-2 and perlecan is available to lens epithelial cells. Exp Eye Res 120, 10–14, doi: 
10.1016/j.exer.2013.12.004 (2014).
24. Danysh, B. P. & Duncan, M. K. The lens capsule. Exp Eye Res 88, 151–164, doi: 10.1016/j.exer.2008.08.002 (2009).
25. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat Med 9, 669–676, doi: 10.1038/nm0603-669 
(2003).
26. Belotti, D. et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by 
ovarian carcinoma cells: implications for ascites formation. Cancer Res 63, 5224–5229 (2003).
27. Wormstone, I. M., Tamiya, S., Anderson, I. & Duncan, G. TGF-beta 2-induced matrix modification and cell transdifferentiation in 
the human lens capsular bag. Investigative Ophthalmology & Visual Science 43, 2301–2308 (2002).
28. Eldred, J. A. et al. MMP2 activity is critical for TGFbeta2-induced matrix contraction–implications for fibrosis. Invest Ophth Vis Sci 
53, 4085–4098, doi: 10.1167/iovs.12-9457 (2012).
29. Kelly, R. J. & Rixe, O. Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 4, 
297–305, doi: 10.1007/s11523-009-0126-9 (2009).
www.nature.com/scientificreports/
1 8Scientific RepoRts | 6:24453 | DOI: 10.1038/srep24453
30. Avery, R. L. et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113, 
363–372 e365, doi: 10.1016/j.ophtha.2005.11.019 (2006).
31. Palejwala, N. V. & Lauer, A. K. Aflibercept: an update on recent milestones achieved. Drugs Today 50, 779–790, doi: 10.1358/
dot.2014.50.12.2245587 (2014).
32. Biagi, C. et al. Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO 
database of adverse drug reactions. Eur J Clin Pharmacol 70, 1505–1512, doi: 10.1007/s00228-014-1755-1 (2014).
33. Ohta, K., Yamagami, S., Taylor, A. W. & Streilein, J. W. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with 
endotoxin-induced uveitis. Invest Ophth Vis Sci 41, 2591–2599 (2000).
34. Wormstone, I. M., Anderson, I. K., Eldred, J. A., Dawes, L. J. & Duncan, G. Short-term exposure to transforming growth factor beta 
induces long-term fibrotic responses. Exp Eye Res 83, 1238–1245, doi: 10.1016/j.exer.2006.06.013 (2006).
35. de Iongh, R. U., Wederell, E., Lovicu, F. J. & McAvoy, J. W. Transforming growth factor-beta-induced epithelial-mesenchymal 
transition in the lens: a model for cataract formation. Cells Tissues Organs 179, 43–55, doi: 10.1159/000084508 (2005).
36. Duncan, G., Wormstone, I. M., Liu, C. S., Marcantonio, J. M. & Davies, P. D. Thapsigargin-coated intraocular lenses inhibit human 
lens cell growth. Nat Med 3, 1026–1028 (1997).
37. Duncan, G., Wang, L., Neilson, G. J. & Wormstone, I. M. Lens cell survival after exposure to stress in the closed capsular bag. Invest 
Ophth Vis Sci 48, 2701–2707, doi: 10.1167/iovs.06-1345 (2007).
38. Maloof, A. J., Pandey, S. K., Neilson, G. & Milverton, E. J. Selective death of lens epithelial cells using demineralized water and Triton 
X-100 with PerfectCapsule sealed capsule irrigation: a histological study in rabbit eyes. Arch Ophthalmol 123, 1378–1384, doi: 
123/10/1378 [pii] 10.1001/archopht.123.10.1378 (2005).
39. Rabsilber, T. M., Limberger, I. J., Reuland, A. J., Holzer, M. P. & Auffarth, G. U. Long-term results of sealed capsule irrigation using 
distilled water to prevent posterior capsule opacification: a prospective clinical randomised trial. Brit J Ophthalmol 91, 912–915, doi: 
10.1136/bjo.2006.106468 (2007).
40. Huang, X. et al. Sustained release of 5-fluorouracil from chitosan nanoparticles surface modified intra ocular lens to prevent 
posterior capsule opacification: an in vitro and in vivo study. J Ocul Pharmacol Th 29, 208–215, doi: 10.1089/jop.2012.0184 (2013).
41. Amoozgar, B., Morarescu, D. & Sheardown, H. Sulfadiazine modified PDMS as a model material with the potential for the 
mitigation of posterior capsule opacification (PCO). Colloid Surface B 111, 15–23, doi: 10.1016/j.colsurfb.2013.05.002 (2013).
42. Davis, J. L. et al. Sustained-release celecoxib from incubated acrylic intraocular lenses suppresses lens epithelial cell growth in an ex 
vivo model of posterior capsule opacity. J Ocul Pharmacol Th 28, 359–368, doi: 10.1089/jop.2011.0196 (2012).
43. Kovach, J. L., Schwartz, S. G., Flynn, H. W. Jr. & Scott, I. U. Anti-VEGF Treatment Strategies for Wet AMD. J Ophthalmol 2012, 
786870, doi: 10.1155/2012/786870 (2012).
44. Wormstone, I. M. et al. Characterisation of TGF-beta 2 signalling and function in a human lens cell line. Exp Eye Res 78, 705–714, 
doi: 10.1016/j.exer.2003.08.006 (2004).
45. Wormstone, I. M. & Eldred, J. A. Experimental models for posterior capsule opacification research. Exp Eye Res 142, 2–12, doi: 
10.1016/j.exer.2015.04.021 (2016).
Acknowledgements
The authors would like to thank Dr Sarah Russell and Sarah Gardner for technical assistance; members of the 
Norwich Eye Research Group for their support; Prof John Reddan for kindly providing the FHL 124 lens cell line; 
and staff, especially Mary Tottman, at the East Anglian and Bristol Eye Banks. Fight for Sight (IMW & DJS) and 
the Humane Research Trust (IMW).
Author Contributions
J.A.E., D.J.S. and I.M.W. conceived the original idea. J.A.E., M.M., H.S.W. and I.M.W. carried out the experiments. 
All authors contributed to the writing of the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: J.A.E., M.M., H.S.W. and I.M.W. have no competing interests relating to the 
work presented. DJS is a consultant to AVS/Santen and AnewOptic Inc.
How to cite this article: Eldred, J. A. et al. Growth factor restriction impedes progression of wound healing 
following cataract surgery: identification of VEGF as a putative therapeutic target. Sci. Rep. 6, 24453; doi: 
10.1038/srep24453 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
